These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 20449878

  • 1. Oral cladribine and fingolimod for relapsing multiple sclerosis.
    Li H, Zhang X.
    N Engl J Med; 2010 May 06; 362(18):1738-9; author reply 1739-40. PubMed ID: 20449878
    [No Abstract] [Full Text] [Related]

  • 2. Oral cladribine and fingolimod for relapsing multiple sclerosis.
    Mann H.
    N Engl J Med; 2010 May 06; 362(18):1738; author reply 1739-40. PubMed ID: 20445188
    [No Abstract] [Full Text] [Related]

  • 3. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):416-26. PubMed ID: 20089960
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC.
    Expert Rev Neurother; 2010 Mar 04; 10(3):365-75. PubMed ID: 20187859
    [Abstract] [Full Text] [Related]

  • 6. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun 04; 9(3):198. PubMed ID: 19527090
    [No Abstract] [Full Text] [Related]

  • 7. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP, Weissert R.
    Clin Neuropharmacol; 2011 Jun 04; 34(1):28-35. PubMed ID: 21242742
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cladribine for multiple sclerosis.
    Drug Ther Bull; 2018 Feb 04; 56(2):21-24. PubMed ID: 29449328
    [Abstract] [Full Text] [Related]

  • 11. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
    Mankinen P, Lundström T, Soini E, Sumelahti ML, Ruutiainen J, Niskala U, Järvinen E.
    Adv Ther; 2020 Feb 04; 37(2):800-818. PubMed ID: 31873868
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.
    Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Lechner-Scott J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand'Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermode A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H, MSBase Study Group.
    Mult Scler; 2018 Oct 04; 24(12):1617-1626. PubMed ID: 28857680
    [Abstract] [Full Text] [Related]

  • 15. Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.
    Esposito F, Radaelli M, Martinelli V, Sormani MP, Martinelli Boneschi F, Moiola L, Rocca MA, Rodegher M, Comi G.
    Mult Scler; 2010 Dec 04; 16(12):1490-9. PubMed ID: 20810516
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cladribine in multiple sclerosis: pitfalls in a new treatment landscape.
    Paul F.
    Expert Opin Pharmacother; 2013 Jan 04; 14(1):1-3. PubMed ID: 23256603
    [No Abstract] [Full Text] [Related]

  • 18. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
    Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z.
    Acta Neurol Scand; 2004 Jun 04; 109(6):390-2. PubMed ID: 15147461
    [Abstract] [Full Text] [Related]

  • 19. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
    Hecht B.
    Med Monatsschr Pharm; 2010 Apr 04; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
    Poveda JL, Trillo JL, Rubio-Terrés C, Rubio-Rodríguez D, Polanco A, Torres C.
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun 04; 20(3):295-303. PubMed ID: 31220959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.